Gour Medical SA entered into a definitive worldwide license agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Actelion Pharmaceuticals Ltd on March 10, 2015. Under the terms of the agreement, Actelion will receive an upfront payment and will be eligible to receive further payments subject to potential development and regulatory milestones, as well as royalties on sales if the compound is commercialized.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 EUR | -.--% | -.--% | +300.00% |
2023 | Gour Medical SA announced that it has received â¬0.135 million in funding | CI |
2023 | Gour Medical SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
- Stock Market
- Equities
- MLCOT Stock
- News Coretech 5
- Actelion Pharmaceuticals Ltd entered into a definitive worldwide license agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Gour Medical SA.